Hikma Pharmaceuticals (HKMPY) Earning Somewhat Positive Press Coverage, Study Finds

Share on StockTwits

Media coverage about Hikma Pharmaceuticals (OTCMKTS:HKMPY) has trended somewhat positive on Wednesday, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a media sentiment score of 1.17 on their scale. InfoTrie also assigned media headlines about the company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company’s share price in the near term.

Shares of Hikma Pharmaceuticals stock remained flat at $$45.44 on Wednesday. Hikma Pharmaceuticals has a 52 week low of $24.60 and a 52 week high of $52.40.

TRADEMARK VIOLATION NOTICE: “Hikma Pharmaceuticals (HKMPY) Earning Somewhat Positive Press Coverage, Study Finds” was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://weekherald.com/2018/11/07/hikma-pharmaceuticals-hkmpy-earning-somewhat-positive-press-coverage-study-finds.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Featured Article: Market Capitalization

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply